Business
NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors
Sequence LifeScienceTM Led Financing to Close on Acquisition of Celularity with Strategic Investment of $5.5 Million LANGHORNE, Pa., May 06, 2026 (GLOBE
About this update from Nexgel, Inc
Sequence LifeScienceTM Led Financing to Close on Acquisition of Celularity with Strategic Investment of $5.5 Million LANGHORNE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Brian J. Kieser, CPA, and Kevin Harris, CFA, to the Board of Directors. Mr. Kieser is currently the CEO and Mr. Harris is the COO of Sequence LifeScienceTM, which recently led the financing to close on the acquisition of Celularity Inc.’s degenerative disease segment with a $5.5 million strategic investment. Adam Levy, Chief Executive Officer of NEXGEL, stated, “Sequence LifeScienceTM has been a great partner in leading our financing round and supporting the closing of our milestone transaction. This marks a transformative moment for NEXGEL and on behalf of the rest of the board and senior management at the Company we welcome Brian and Kevin to our Board of Directors. We could not ask for better strategic partners. Brian and Kevin bring industry experience, product innovation, and a strong distribution system to help us grow and expand the potential of our new acquisition.” “Kevin and I are honored to serve on NEXGEL’s Board of Directors at such an exciting time for the Company,” said Brian Kieser, CEO of Sequence LifeScienceTM. “We look forward to working closely with the leadership team to strengthen the partnership between our organizations, build on our shared vision, and support NEXGEL’s continued growth and innovation.” About Brian J. Kieser, CPABrian J. Kieser the Founder and Chief Executive Officer of Fountainhead Biomedical Holdings, a San Antonio–based venture platform designed to create, scale, and commercialize next-generation medical technologies. Through Fountainhead Biomedical Holdings, Mr. Kieser has assembled a vertically integrated ecosystem of companies focused on orthopedic medical devices, regenerative biologics, and advanced biomedical manufacturing. The platform includes Nvision Biomedical Technologies, Sequence LifeScience, and Lockhill Advanced Manufacturing Technologies—each purpose-built to solve critical challenges in surgery, tissue healing, and medical device production. Prior to Fountainhead,...